Trump Administration Launches Review of Abortion Pill Safety Protocols

The Trump administration has begun a critical review of the safety protocols for the abortion pill mifepristone, amidst ongoing efforts by conservative states to limit access, according to reports from The Hill.

A correspondence sent earlier in September, and now made public, indicates Secretary of Health and Human Services Robert F. Kennedy Jr. and FDA Commissioner Marty Makary are considering alterations to the Risk Evaluation and Mitigation Strategy requirements. This decision is informed by recent studies, which raise doubts about mifepristone’s safety. They stated that the HHS will conduct its own independent review of the drug.

Several states have facilitated processes to challenge those who sidestep laws to procure abortion pills. The situation in Texas is particularly noteworthy. The state now empowers private citizens to file lawsuits against anyone involved in the manufacturing, shipment, or supply of abortion drugs, with the potential for damages up to $100,000. However, individuals using the pills are exempt from this provision.

In a move that underscores the tension surrounding this issue, Texas Attorney General Ken Paxton issued cease-and-desist orders to various organizations, mandating them to halt the advertising, sale, and shipment of abortion-inducing drugs into Texas. Citing two recent instances where individuals allegedly obtained such drugs illegally, Paxton declared, “Texas will not tolerate the murdering of innocent life through illegal drug trafficking.”

The FDA initially approved mifepristone in 2000 for pregnancy termination up to seven weeks, but subsequent modifications in 2016 and 2021 have expanded its permissible use. These changes include increasing the gestational age limit to 10 weeks, allowing the drug to be mailed to patients, lowering the dosage, approving telehealth prescribing, and authorizing healthcare providers beyond physicians to prescribe the drug.

You May Also Like: FBI Seizes Classified Documents from John Bolton’s Office

While Kennedy and Makary have not directly advocated for the withdrawal of the drug, they referenced a study by the Ethics and Public Policy Center (EPPC) to support their case for reevaluating the Biden administration’s changes, noting that safety measures for women using mifepristone have been significantly reduced.

As this review process unfolds, the potential implications for women’s reproductive rights and the ongoing battle over abortion access in the United States are significant. With many questions still unanswered, the importance of staying informed cannot be overstressed.